RT Journal Article
SR Electronic
T1 Early metabolic disruption and predictive biomarkers of delayed-cerebral ischemia in aneurysmal subarachnoid haemorrhage
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.26.23289184
DO 10.1101/2023.04.26.23289184
A1 Chikh, Karim
A1 Tonon, David
A1 Triglia, Thibaut
A1 Lagier, David
A1 Buisson, Anouk
A1 Alessi, Marie-Christine
A1 Defoort, Catherine
A1 Benatia, Sherazade
A1 Velly, Lionel J
A1 Bruder, Nicolas
A1 Martin, Jean-Charles
YR 2023
UL http://medrxiv.org/content/early/2023/05/02/2023.04.26.23289184.abstract
AB BACKGROUND Delayed cerebral ischaemia (DCI) following aneurysmal subarachnoid haemorrhage (aSAH) is a major cause of complications and death. Here we set out to identify high-performance predictive biomarkers of DCI and its underlying metabolic disruptions using metabolomics and lipidomics approaches.METHODS This single-centre retrospective observational study enrolled 61 consecutive patients with severe aSAH requiring external ventricular drainage between 2013 and 2016. Of these 61 patients, 22 experienced a DCI and were classified as DCI+ and the other 39 patients were classified as DCI-. A further 9 patients with other neurological features were included as non aSAH controls. Blood and cerebrospinal fluid (CSF) were sampled within the first 24 h after admission. We carried out LC-MS/MS-based plasma and CSF metabolomic profiling together with total lipid fatty acids analysis.RESULTS We identified a panel of 20 metabolites that together showed high predictive performance for DCI (area under the receiver operating characteristic curve: 0.968, specificity: 0.88, sensitivity: 0.94). This panel of metabolites included lactate, cotinine, salicylate, 6 phosphatidylcholines, and 4 sphingomyelins. Analysis of the whole set of metabolites to highlight early biological disruptions that might explain the subsequent DCI found peripheral hypoxia driven mainly by higher blood lactate, arginine and proline metabolism likely associated to vascular NO, dysregulation of the citric acid cycle in the brain, defective peripheral energy metabolism and disrupted ceramide/sphingolipid metabolism. We also unexpectedly found a potential influence of gut microbiota on the onset of DCI.CONCLUSION We identified a high-performance predictive metabolomic/lipidomic signature of further DCI in aSAH patients at admission to a NeuroCritical Care Unit. This signature is associated with significant peripheral and cerebral biological dysregulations. We also found evidence, for the first time, pointing to a possible gut microbiota/brain DCI axis, and proposed the putative microorganisms involved.Clinical trial registration Clinicaltrials.gov identifier: NCT02397759Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02397759Funding StatementThis work was partly supported by the Assistance Publique des Hôpitaux de Marseille (AORC project No. 2012-54). None of the authors or their institutions at any time received payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study (N8 2013-1316) was provided by the Ethical Committee of the Assistance Public Hôpitaux de Marseille,France (Chairperson Professor Jammes) on 16 May 2013I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll the data used in the manuscript are available upon request to jean-charles.martin@univ-amu.fr, except those excluded for ethical reasons.WFNSWorld Federation of Neurological SurgeonsIVHintraventricular haemorrhagePCAprincipal component analysisPLS-DApartial least squares–discriminant analysisGOSEGlasgow Outcome Scale ExtendedVIPvariable importance in projection coefficientFDRfalse discovery rateHILIChydrophilic interaction liquid chromatographyRPreverse-phase chromatography